logo
Plus   Neg
Share
Email

Catalyst Pharmaceutical Partners (CPRX) Is Climbing On FDA News

Catalyst Pharmaceutical Partners (CPRX) announced after the close Tuesday that the FDA has accepted its New Drug Application for Firdapse for a Priority Review. The drug is a treatment for Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceutical Partners has been rising since the open of trade Wednesday and is now up 0.30 at $3.84. The stock has climbed to over a 4-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>